Immunomedics nabs therapy patent for Japanese market

Radiopharmaceutical developer Immunomedics of Morris Plains, NJ, has received a patent in Japan for a humanized antibody to be used in the treatment of non-Hodgkin's lymphoma. The antibody, epratuzumab, is in clinical tests as a therapy against CD22 expressed on non-Hodgkin's lymphoma and other B-cells. The agent is the company's most advanced cancer therapeutic in development, Immunomedics said.

By AuntMinnie.com staff writers
April 17, 2000
Copyright © 2000 AuntMinnie.com
Page 1 of 116
Next Page